Search
Now showing items 1-1 of 1
Safety and efficacy of T-DM1 in patients with advanced HER2-positive breast cancer The Royal Marsden experience.
(Elsevier BV, 2020-01-01)
BACKGROUND: Ado-trastuzumab emtansine (T-DM1) is standard of care for patients with advanced HER2+ breast cancer who relapse within 6 months of adjuvant trastuzumab or progress on first-line anti-HER2 therapy. We evaluated ...